



BIOCRYST TO HOST REVIEW OF RESULTS FROM PHASE I-II STUDY OF BCX-1777 AT SPECIAL BREAKFAST BRIEFING DURING THE 2003 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

Birmingham, Alabama - December 2, 2003 - BioCryst Pharmaceuticals, Inc. (Nasdaq NM: BCRX) announced that the company will host a special breakfast briefing during the annual meeting of the American Society of Hematology on Monday, December 8, 2003 at 6:00 a.m. local time (9:00 a.m. EST) in San Diego, California. Results of the Phase I-II study of intravenous BCX-1777 in relapsed or refractory aggressive T-cell malignancies will be presented by Dr. Deborah Thomas, M.D. Anderson Cancer Center, Principal Investigator for the study. Dr. Charles E. Bugg, Ph.D., Chairman and CEO, and Dr. J. Claude Bennett, President and COO, will participate in the question and answer period following Dr. Thomas' formal remarks.

Interested investors can listen to the presentation live over the Internet during the conference at the following address:

<http://www.shareholder.com/biocryst/MediaRegister.cfm?MedialD=10058>

What:

Review of Results from Phase I-II Study BCX-1777

When:

Monday, December 8, 2003, at 9:00 a.m. EST

Where:

American Society of Hematology Annual Meeting
Sheraton San Diego Hotel & Marina
1380 Harbor Island Drive
San Diego, California

For those unable to listen at the designated time, the webcast will remain available for replay on <http://www.shareholder.com/biocryst/medialist.cfm> for 90 days following the conference.

Founded in 1986, BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of small-molecule pharmaceuticals to treat cancer, cardiovascular and autoimmune diseases, and viral infections.